HHS Secretary Robert F. Kennedy Jr. outlined six measures designed to curb chemical and surgical interventions for minors, including a formal declaration that sex-rejecting medical procedures lack sufficient evidence of safety and long-term benefit. Among the steps announced, the Centers for Medicare and Medicaid Services (CMS) will introduce new rules barring hospitals from using federal funds to provide such treatments to individuals under 18.

The Food and Drug Administration (FDA) will also issue warnings to manufacturers accused of illegally marketing breast binders to children, citing concerns over physical and psychological harm. HHS officials said the measures reflect a renewed focus on child protection and medical ethics, emphasizing caution in pediatric care.

The announcement follows action in Congress, where the U.S. House of Representatives earlier this week passed legislation that could impose criminal penalties on healthcare providers who administer gender-related medical treatments to minors. Supporters of the bill argue it is necessary to safeguard children, while critics warn it could limit access to care and escalate legal disputes.

The policy shift marks a significant departure from previous federal approaches to transgender healthcare and is expected to face legal challenges, as states, medical associations, and advocacy groups debate the future of pediatric gender related treatments in the United States.

President Donald Trump, speaking at the White House following the Senate votes, sharply criticized Obamacare, calling the program “horrible” and arguing that it primarily benefits insurance companies rather than patients. Trump said that instead of subsidizing insurers, “billions of dollars should go directly to the people,” proposing the use of health or insurance savings accounts that would give individuals greater control over their healthcare spending. He also addressed concerns raised by some Republicans regarding potential abortion-related funding tied to ACA subsidies.

The expiring subsidies, which were expanded under previous legislation to lower monthly premiums, currently support more than 22 million Americans who purchase coverage through ACA marketplaces. Without congressional action, premiums are expected to rise sharply in 2026, potentially pricing many lower- and middle-income households out of coverage. Supporters of extending the subsidies warned of increased uninsured rates and financial strain on families, while opponents cited long-term costs and ideological objections to the program.

President Donald Trump argue that allowing the Affordable Care Act’s expanded subsidies to expire represents a long overdue correction to a system they say prioritized insurance companies over patients. Under Obamacare, critics contend that billions of taxpayer dollars were routed through insurers, inflating premiums, narrowing provider networks, and limiting choice, while doing little to address the root causes of rising healthcare costs. Despite its promises, the system left many Americans paying higher deductibles and struggling to access timely care.

President Trump has proposed a fundamentally different approach one that puts money directly into the hands of Americans rather than institutions. By redirecting funds into health savings or insurance accounts, the administration says individuals would gain greater control over their healthcare decisions, increased transparency in pricing, and the freedom to choose plans and providers that best suit their needs. Supporters argue this market-driven model encourages competition, lowers costs over time, and empowers patients instead of bureaucracies.

Trump’s approach reflects a broader shift away from government-managed healthcare toward personal ownership, flexibility, and accountability, marking a clear departure from the Obama-era framework. Advocates believe the change opens the door to innovation, fairer pricing, and a healthcare system that serves people first restoring choice, dignity, and control to American families.